within Pharmacolibrary.Drugs.ATC.C;

model C05BB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.0,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Invert sugar is a mixture of glucose and fructose produced by the hydrolysis of sucrose. It has been used historically as a plasma volume expander and as a source of carbohydrate calories in parenteral nutrition, particularly when glucose administration is undesirable (e.g., hereditary fructose intolerance). It is not a commonly approved drug for clinical use today.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic parameters for invert sugar (ATC code C05BB03) could be found in published literature for administration as a medicinal product in humans.</p><h4>References</h4><ol><li>Ewald Roemer, Matthias K Schorp, Jean-Jacques Piad√©, Jeffrey I Seeman, Donald E Leyden, Hans-Juergen Haussmann,Scientific assessment of the use of sugars as cigarette tobacco ingredients: a review of published and other publicly available studies.,Critical reviews in toxicology,2012<a href='https://pubmed.ncbi.nlm.nih.gov/22263649/'>https://pubmed.ncbi.nlm.nih.gov/22263649/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C05BB03;
